Clinical research
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 20, 2020.
BMS and Exelixis Eye Potential Approval of RCC Combination Drug Following Positive Phase III Results
This morning, the two companies announced the positive topline results from the pivotal Phase III CheckMate -9ER study in previously untreated patients with renal cell carcinoma.
Swiss pharma giant Novartis will launch a Phase III trial assessing hydroxychloroquine for the treatment of COVID-19. The trial will be conducted across the United States.
Sanjeev Luther, president and chief executive officer of Rafael Pharmaceuticals, told BioSpace that the company made the decision to continue to enroll the trial, which was 75% filled, due to the short timeline patients with metastatic pancreatic cancer have.
There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look.
A recent study published in JAMA Oncology found that although about a third of cancer clinical trials failed to meet their primary endpoints, at oncology meetings they tend to be spun in a positive light.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 17, 2020.
Data from the ongoing Phase II trial, as well as results from the Phase I trial of VR-2218, was released during a live webcast presentation on Wednesday.
In a controlled laboratory test, Eagle Pharmaceuticals’ malignant hyperthermia treatment Ryanodex (dantrolene sodium) inhibited the growth of SARS-CoV-2, the virus causing the COVID-19 pandemic.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 16, 2020.
PRESS RELEASES